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Abstract
 
Pretreatment of rodent hearts with platelet-derived growth factor (PDGF)–AB decreases myo-
cardial injury after coronary occlusion. However, PDGF-AB cardioprotection is diminished in
older animals, suggesting that downstream elements mediating and/or synergizing the actions of
PDGF-AB may be limited in aging cardiac vasculature. In vitro PDGF-AB induced vascular endo-
thelial growth factor (VEGF) and angiopoietin (Ang)-2 expression in 4-mo-old rat cardiac endo-
thelial cells, but not in 24-mo-old heart cells. In vivo injection of young hearts with PDGF-AB
increased densities of microvessels staining for VEGF and its receptor, Flk-1, and Ang-2 and its
receptor, Tie-2, as well as PDGF receptor (PDGFR)–
 
 
 
. In older hearts, PDGF-AB–mediated
induction was primarily limited to PDGFR-
 
 
 
. Studies in a murine cardiac transplantation model
demonstrated that synergist interactions of PDGF-AB plus VEGF plus Ang-2 (PVA) provided an
immediate restoration of senescent cardiac vascular function. Moreover, PVA injection in young
rat hearts, but not PDGF-AB alone or other cytokine combinations, at the time of coronary
occlusion suppressed acute myocardial cell death by 
 
 
 
50%. However, PVA also reduced the
extent of myocardial infarction with an age-associated cardioprotective benefit (4-mo-old with
45% reduction vs. 24-mo-old with 24%; P 
 
  
 
0.05). These studies showed that synergistic cytokine
pathways augmenting the actions of PDGF-AB are limited in older hearts, suggesting that strategies
based on these interactions may provide age-dependent clinical cardiovascular benefit.
Key words: platelet-derived growth factor • vascular endothelial growth factor • 
angiopoietin • myocardial infarction • apoptosis
 
Introduction
 
Vascular dysfunction is associated with aging (1, 2) and is
linked to an increased risk of cardiovascular events (3, 4).
Recently, we demonstrated that impaired expression of
the platelet-derived growth factor (PDGF)–AB heterodimer
by cardiac microvascular endothelial cells (CMECs) and
endothelial progenitor cells contributes to this vascular
dysfunction and diminishes cardiac angiogenesis in older
rodents (5, 6). Experimentally, intramyocardial delivery of
PDGF-AB before coronary occlusion decreases the extent
of myocardial injury (5). However, this protection is effec-
tive only when PDGF-AB is delivered before, but not at
the time of, coronary occlusion. Moreover, this protection
is greater in younger rodent hearts than in older hearts,
suggesting that pathways mediating and/or synergizing
with the cardiovascular actions of PDGF-AB may be lim-
ited with age.
Aging is also associated with significant dysregulation in
the expression of vascular endothelial growth factor
(VEGF; 6, 7) that is induced by PDGF-AB in young
CMECs (8). Restoration of VEGF in older mice does not
independently rescue senescent cardiac angiogenic function
(5), suggesting that its role may be to augment the actions
of other cytokines in PDGF-AB–mediated cardioprotection.
To this end, the combination of PDGF-AB and VEGF has
been reported recently to synergistically enhance the rapid
formation of mature vascular networks (9). VEGF has also
been shown to have cross-regulation and dependency with
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angiopoietins (Angs) in angiogenic regulation (10–12), sug-
gesting that VEGF and Angs may have important roles in
PDGF-AB–induced cardioprotection.
The decrease in infarction size after PDGF-AB injection
may not be mediated solely by angiogenic induction. Pa-
pers have demonstrated that vascular cytokines have a pro-
found effect in preventing apoptosis (13–15), which is re-
sponsible for a significant proportion of the early loss of
myocytes and endothelial cells observed after acute coro-
nary occlusion (16, 17). Experimental antiapoptotic thera-
pies can reduce myocardial infarction size after coronary
occlusion (18, 19), suggesting that a suppression of cardiac
apoptosis may contribute to the cardioprotective actions of
PDGF-AB pathways. Indeed, in the older rat heart,
PDGF-AB can reverse the senescent proapoptotic en-
hancement in tumor necrosis factor receptor signaling to
reduce mortality after acute coronary occlusion (20).
Here, we report that cardioprotection by PDGF-AB is
mediated by the induction of cytokines and receptors,
which act synergistically with PDGF-AB to rapidly sup-
press cardiac apoptosis and reduce the extent of myocardial
injury in both young and old rodent hearts. However, se-
nescent changes in these cytokine pathways downstream of
PDGF-AB limit cardioprotection of the older rat heart.
 
Materials and Methods
 
Animals.
 
Studies using 4- and 24-mo-old F344 rats and neo-
natal and 18-mo-old C57BL/6 mice were performed in compli-
ance with the Institutional Animal Care and Use Committee of
Weill Medical College of Cornell University.
 
Molecular Analysis of Age-associated PDGF Cytokine Pathways.
 
To define the potential age-associated changes in growth factor
pathways downstream of PDGF-AB, CMECs were isolated from
young (4-mo-old) and old (24-mo-old) rat hearts, as described
previously (20). Cells treated with PDGF-AB and expression lev-
els of the proangiogenic cytokines VEGF and Ang-2 were as-
sessed by real time RT-PCR. In brief, rat hearts were harvested
and digested using 0.2% collagenase and 0.005% DNase in 10 ml
of complete media (DMEM with 10% FCS, 50 
 
 
 
g/ml of endo-
thelial growth supplement [Sigma-Aldrich], 30 U/ml heparin,
100 U/ml penicillin, and 100 
 
 
 
g/ml streptomycin) for 45 min at
37
 
 
 
C. Endothelial cells were isolated by incubating the cell sus-
pensions with anti-CD31 coated Dynabeads (Dynal) for 30 min
at room temperature and collected with a magnetic particle col-
lector. Cells were cultured up to four passages. 2 h before PDGF-
AB treatment, the cells were fed with basic media (without serum
and endothelial growth supplement) after which 50 ng/ml
PDGF-AB (R&D Systems) was added to the wells. Total RNA
was isolated at different time points (0, 15 min, 30 min, 1 h, 3 h,
and 6 h; 
 
n
 
 
 
 
 
 3 wells/time point) using a Rneasy Mini Kit
(QIAGEN). cDNA was prepared using Sensisript™ Reverse
Transcriptase Kit (QIAGEN). Real-time PCR reactions were
performed using 2 
 
 
 
l of cDNA with SYBR
 
®
 
 green hot start
PCR protocol (Applied Biosystems) with 
 
 
 
-actin levels, deter-
mined from serial dilutions of cDNA to generate standard curves,
and used as controls (95
 
 
 
C for a 600-s hot start, denaturing at
95
 
 
 
C for 30 s, and annealing at 60
 
 
 
C for 30 s and at 72
 
 
 
C for 30 s
for a maximum of 40 cycles). All experiments were replicated
with independent isolations of cells. The following primer pairs
 
were used: 
 
 
 
-actin, forward, 5
 
 
 
-GTCGTACCACTGGCAT-
TGTC-3
 
 
 
, reverse, 5
 
 
 
-ACCCTCATAGATGGGCACAG-3
 
 
 
;
Ang-2, forward, 5
 
 
 
-TCCGGCGAGGAGTCTAACTA-3
 
 
 
, re-
verse, 5
 
 
 
-AGCTGGAAAAGCAGAAGCTG-3
 
 
 
; and VEGF,
forward, 5
 
 
 
-TGCCTACCTCACCTGTTTCC-3
 
 
 
, reverse, 5
 
 
 
-
TCTGTCTGGCTGTCATCTGG-3
 
 
 
.
 
In Situ Analysis of PDGF Downstream Pathways.
 
To define
the in vivo induction of protein patterns of growth factor path-
ways downstream of PDGF-AB, cardiac tissue was analyzed by
immunostaining for VEGF, Ang-1, Ang-2, Flk-1, Flt-1, Tie-1,
Tie-2, and PDGFR-
 
 
 
. Sets of young adult and old rats were
anesthetized and underwent left intercostal thoracotomy and re-
ceived intramyocardial injections of PDGF-AB or PBS (
 
n
 
 
 
 
 
 3
per group). After identifying the left anterior descending artery
(LAD), PDGF-AB (100 ng/50 
 
 
 
l in PBS) or PBS alone was in-
jected through a 30-gauge needle (two 25 
 
 
 
l injections, 2 mm
apart) in the mid–left ventricular anterior wall. The chest wall
was closed, the lungs were inflated, the rats were extubated, and
the tracheotomy was closed. Rats were killed 24 h after injection,
and hearts were excised, fixed, and sectioned for immunohis-
tochemistry staining. Rabbit or goat antibodies directed to
VEGF, Ang-1, and Ang-2, Flk-1, Flt-1, Tie-1, Tie-2, and
PDGFR-
 
 
 
 (ABC Staining Kit; Santa Cruz Biotechnology, Inc.)
were used as primary antibodies and visualized using the ABC
staining method (DakoCytomation). Positive vessel numbers
were assessed in sections at the mid–papillary level of each heart
and all stained luminal structures in a total of six high-power
fields (40
 
 
 
) per section were identified in a blinded analysis as
described previously (5, 21, 22).
 
Senescent Cardiac Allograft Assay.
 
To test the physiological sig-
nificance of the alterations in aging endothelial function, we used
a cardiac allograft model, which allows the assessment of cardiac
angiogenic potential in different age groups (5, 6). In this model,
allograft neovascularization is mediated by host endothelial cells,
which are recruited to the donor hearts and recapitulate the car-
diac myocyte–endothelial cell communication in vivo (23). In
brief, 18-mo-old C57BL/6 mice were anesthetized with 15 
 
 
 
g/
ml avertin and a dose of 10 
 
 
 
l solution containing 0, 1, 3, 10, or
100 ng (
 
n
 
 
 
 
 
 20 for each group) of PDGB-AB was injected sub-
cutaneously into each ear. C57BL/6 neonatal hearts were trans-
planted either at the time of, or 24 h after, injection into the sub-
cutaneous pinnal tissue on the dorsal side of the ear. Allograft
viability was scored by pinnal and transplant integrity 1 wk after
engraftment, as we have described previously (5, 6). Additional
sets of senescent hosts also were pretreated with subcutaneous
pinnal injections of 3 ng PDGF-AB, 100 ng VEGF, and 3 ng
PDGF-AB plus 100 ng VEGF, 100 ng Ang-2, or PBS alone (
 
n
 
 
 
 
 
20 for each group) 24 h before transplantation. Transplantations
at the time of injection were performed with sets of ears treated
with VEGF, PDGF-AB, Ang-2, and PDGF-AB plus VEGF,
PDGF-AB plus Ang-2, VEGF plus Ang-2), PDGF-AB plus
VEGF plus Ang-2 (PVA; 100 ng of each cytokine), or PBS (
 
n
 
 
 
 
 
10 for each group).
 
Concomitant Injection of VEGF and Ang-2 with PDGF-AB at the
Time of Ligation.
 
To study the potential synergism between
PDGF-AB and its downstream growth factors in the intact rat
heart, combinations of growth factors were injected intramyocar-
dially at the time of coronary occlusion. Sets of 4-mo-old rats
were injected with combinations of PVA as well as PDGF-AB
alone or PBS (100 ng of each in a total of 50 
 
 
 
l of PBS; 
 
n
 
 
 
 
 
 3
per group) as aforementioned, and the LAD was ligated just be-
low the left atrial appendage with 8-0 nylon sutures. Pallor and
regional wall motion abnormality of the left ventricle as well as 
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ST segment elevation confirmed occlusion. These rats were
killed 24 h after ligation. Hearts were excised and fixed, sections
were analyzed for apoptotic cell death using TUNEL (terminal
deoxynucleotidyl transferase-mediated dUTP) staining (In Situ
Cell Death Kit; Roche). In brief, slides were deparaffinized and
rehydrated using histoclear and decreased grades of alcohol. After
digestion in 10 
 
 
 
g/ml proteinase-k, slides were incubated in a
mixture of TdT, dNTP, and dUDP-TMR for 1 h at 37
 
 
 
C
and counterstained with 4
 
 
 
,6-diamidino-2-phenylindole (Inno-
Genex). Micrographs were taken using both low magnification
(4
 
 
 
) and higher magnification (40
 
 
 
) using fluorescent micros-
copy. Apoptotic cell density in the anterior left ventricular wall
was measured in 15 high-power fields/heart. The extent of car-
diac tissue apoptosis was assessed on reconstructed 4
 
 
 
 micro-
graphs using National Institutes of Health Image J analyzing sys-
tem and expressed as percentage of left ventricular area.
Additional sets of both 4- and 24-mo-old rats received injec-
tions of PVA combination, PDGF-AB alone, or PBS alone (
 
n
 
 
 
 
 
 5
for each group) at the time of LAD ligation. The LAD was ligated
just below the left atrial appendage in 4-mo-old rats and 2 mm be-
low the appendage in the old rats to avoid excess mortality in the
older rats as described previously (20). These rats were killed 14 d
after ligation, and sections at the mid–papillary level were stained
by Masson’s trichrome stain as a measure of the extent of myocar-
dial injury as blinded analysis as described previously (5, 20).
 
Statistics.
 
Differences in positive vessel numbers and apop-
totic cell numbers were analyzed by the Student’s 
 
t
 
 test. The ex-
tent of myocardial infarction was compared using Fisher’s test. A
value of P 
 
  
 
0.05 was considered significant.
 
Results
 
Induction of VEGF and Ang-2 by PDGF Pretreatment.
 
Real-time RT-PCR revealed that PDGF-AB induced sig-
nificant increases in the expression of both VEGF and Ang-2
in the young, but not old, rat CMECs (Fig. 1 A). How-
ever, at the baseline, the older cells expressed higher levels
of VEGF, similar to our previous findings with murine
CMECs (5). In response to PDGF-AB, cytokine transcripts
in the young CMECs showed an initial rise, peaking at be-
tween 30 min and 1 h, followed by a subsequent down-
regulation of expression later in the time course. The older
Figure 1. PDGF-AB induction
of cardiac microvascular endo-
thelial proangiogenic cytokines.
(A) Real-time RT-PCR of VEGF
and Ang-2 in PDGF-AB treated
4- and 24-mo-old rat CMECs in
vitro. (B) Representative immu-
nohistochemical staining of VEGF
or Ang-2 in cardiac capillaries in
rat hearts injected with vehicle
(PBS) or PDGF-AB 24 h before
euthanization (n    3, each).
Bar   10  m. (C) Graph shows
the densities of VEGF and Ang-2
positive capillaries in PDGF-AB–
or PBS-treated hearts. *, P   0.05;
**, P   0.005. Treatment versus
control.
Figure 2. Age-associated induction of cytokine receptors by intramyo-
cardial injection of PDGF-AB. Representative immunohistochemical
staining of PDGFR- , Flk-1, and Tie-2 in cardiac capillaries in rat hearts
injected with vehicle (PBS) or PDGF-AB 24 h before euthanization in 4-
and 24-mo-old hearts (n   3, each). Bar   10  m. Graph shows the
densities of PDGFR- , Flk-1, and Tie-2 positive capillaries (mm2) in
PDGF-AB– or PBS-treated hearts. *, P   0.05. PDGF-AB versus PBS. 
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cells were also responsive to PDGF-AB, however, only
with a negative regulation of both VEGF and Ang-2 levels.
Immunohistological staining revealed in vivo induction of
cardiac cytokines by PDGF-AB in the young hearts. In-
tramyocardial injection of PDGF-AB significantly in-
creased the density of cardiac capillaries stained positive for
VEGF and Ang-2 (but not Ang-1; not depicted) in the
4-mo-old rat hearts sections (Fig. 1, B and C). However,
unlike the in vitro expression patterns of VEGF and Ang-2
in the older CMECs, the density of VEGF and Ang-2 pos-
itive vessels was significantly lower in the 24-mo-old rat
hearts both in the control and PDGF-AB–treated sections
compared with staining patterns in the young hearts. In-
deed, PDGF-AB injection in the old hearts did not signifi-
cantly alter VEGF density and resulted in only modest in-
creases in Ang-2 patterns.
Based on the highly localized staining patterns of VEGF
and Ang-2 in the young, but not old hearts, additional im-
munohistochemistry was performed to assess potential dif-
ferences in receptors for these cytokines. Staining of sec-
tions of PBS-treated rat hearts revealed Flk-1, a VEGF
receptor, and Tie-2, an Ang receptor, expression in the
cardiac microvasculature of both age sets (Fig. 2) with ap-
proximately twofold higher density in the young hearts.
PDGFR-
 
 
 
 was present in the PBS-treated young hearts,
but was significantly diminished in the aging control car-
diac tissue. PDGF-AB significantly increased the density of
all three receptors in the young hearts as well as PDGFR-
 
 
 
in the aging hearts without altering patterning of Flk-1 and
Tie-2. Immunostaining of Flt-1, another VEGF receptor,
and Tie-1, another Ang receptor, revealed sparse localiza-
tion in sections of both ages (unpublished data).
 
PDGF Pathway Synergism in Angiogenesis of Exogenous
Cardiac Tissue
 
The potential cardiac vascular function of
the cytokines in the PDGF-AB pathway was examined in a
senescent cardiac allograft–pinnal transplant model. To de-
tect synergistic interactions with downstream cytokines, a
dose response curve of PDGF-AB restoration of cardiac
vascularization was performed. These studies revealed that
pinnal treatment the day before transplantation with 3 ng
PDGF-AB rescued approximately half of the cardiac al-
lografts in the aging mice (Fig. 3). Previously, we had dem-
onstrated that VEGF was not sufficient to rescue cardiac vi-
ability in this model (5); however, the addition of 100 ng
VEGF augmented the actions of the low dose PDGF-AB,
fully restoring integrity of the transplanted cardiac allografts
(Fig. 3, A and B). Administration of Ang-2 alone was also
fully effective in restoring allograft integrity and so addi-
tional combinations were not studied (Fig. 3 C). Injection
of the ears at the time of transplantation with combinations
of cytokines demonstrated that VEGF and Ang-2 with or
without PDGF-AB synergistically augmented senescent
cardiac allograft viability, shifting the effective temporal
window of pinnal treatment (Fig. 3 D).
 
Figure 3.
 
Cytokine synergism in restoration of senescent cardiac allografts.
(A) Representative examples of neonatal cardiac transplants into 18-mo-old
senescent hosts with pretreatment of VEGF (100 ng) or VEGF (100 ng)
and PDGF-AB (3 ng). The arrowhead (left) indicates the site of necrotic
loss of both allograft and host pinnal tissue beyond the transplant site in
the majority of the VEGF-pretreated transplants. The arrow (right) indi-
cates viable/intact cardiac transplants in the host pinnal tissue. (B) Dose
response curve of PDGF-AB pretreatment in the restoration of cardiac
allograft viability in 18-mo-old mice (
 
n
 
 
 
 
 
 20, per group). 10 ng and 100
ng of PDGF-AB restored a significant number of allografts compared
with 0- and 1-ng doses. P 
 
  
 
0.005. (C) Assessment of VEGF and Ang-2
pretreatment and combined VEGF and PDGF-AB (
 
n
 
 
 
 
 
 20, per group).
 
*
 
, P 
 
  
 
0.05. PDGF-AB (3 ng) versus PBS. 
 
**
 
, P 
 
  
 
0.01. Treatment ver-
sus PDGF-AB (3 ng) or PBS. (D) Assessment of cytokine combinations in
the peri-transplantation of pinnal tissue at the time of cardiac allograft
transplantation (
 
n
 
 
 
  
 
10, per group). 
 
*
 
, P 
 
  
 
0.05. PDGF-AB plus VEGF
plus Ang-2 or VEGF plus Ang-2 versus PBS and all other treatment groups. 
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Enhanced Cardioprotective Kinetics by Concomitant Delivery
of PVA.
 
The synergistic actions of PDGF-AB pathway
cytokines was confirmed in vivo in an acute myocardial in-
farction model with delivery of combinations of growth
factors at the time of coronary occlusion. Results of cardiac
TUNEL staining 24 h after LAD ligation demonstrated
that only the triple combination of PVA limited cardiac cell
death in the young rat heart, reducing both the area and
density of myocardial cell apoptosis (Fig. 4).
Based on the result of these acute cell death studies, the
potential that the triple combination delivered peri-ligation
was assessed 2 wk after myocardial infarction in 4- and 24-
mo-old rat hearts. Using a more distal LAD occlusion to
maintain 14 d postoperative survival in the older hearts
(100% for both 4- and 24-mo-old rats), the control treat-
ment groups did not demonstrate a statistically significant
difference in the extent of myocardial infarction, though
the older hearts trended to have larger areas of injury, simi-
lar to previous observations (5, 20). Injection of PVA at the
time of coronary occlusion reduced the myocardial infarc-
tion size in both young and old rat hearts, with significantly
greater benefit in the young hearts compared with old
hearts treated with PVA relative to age-matched controls
(4-mo-old reduction of 40%; 24-mo-old reduction of 24%;
P 
 
 
 
 0.05; Fig. 5).
 
Discussion
 
In this paper, we have demonstrated that PDGF-AB can
act synergistically with its downstream cytokines, VEGF
and Ang-2, to promote cardioprotection in both young
and old rodent hearts. We had shown previously that
PDGF-AB treatment before coronary occlusion effectively
limits the severity of myocardial infarction (5). Here, we
have extended this finding and shown that the combination
of PVA provides immediate benefit, suppressing cardiac
cell death at the time of acute coronary occlusion and, thus,
reducing myocardial injury within a therapeutically rele-
vant time frame.
The combined actions of PDGF-AB with its induction
of both VEGF and Ang-2 provide an important under-
standing of the cardioprotective effects beyond the proan-
giogenic signaling pathways attributed to these vascular cy-
tokines. The role of VEGF in the augmentation of PDGF-AB
as well as the independent actions of Ang-2 in the senes-
Figure 4. Synergistic suppression of cardiac apoptosis after coronary
occlusion. TUNEL labeling of rat cardiac sections 24 h after injection
with combinations of PDGF-AB, VEGF, and Ang-2 at the time of LAD
ligation. (A) Reconstructed cross-section micrograph from lower magni-
fication (4 ) images for measurement of apoptotic area (percentage of left
ventricular area). (B) High magnification (40 ) TUNEL staining images
used in the quantification of apoptotic cell density. Bar   10  m. (C) A
graph is shown plotting mean apoptotic risk area size (white) and cell
density (TUNEL ; black) in the sections of rat anterior left ventricular
wall injected with PBS, PDGF-AB, PDGF-AB plus VEGF (PV), PDGF-
AB plus Ang-2 (PA), VEGF plus Ang-2 (VA), or PDGF-AB plus VEGF
and Ang-2 (PVA) (n   3, each group) at the time of LAD ligation. *, P  
0.01; **, P   0.005 PVA versus PBS and all other cytokine groups.
Figure 5. Age-associated cardioprotection by combined cytokine injection
at the time of coronary occlusion. (A) Representative Masson’s trichrome
staining of rat hearts harvested 2 wk after peri-occlusion injections of
PBS, PDGF-AB (P), or PDGF-AB plus VEGF and Ang-2 (PVA) and
LAD ligation (n   5, each). Infarction area (blue stain) at the mid–papillary
muscle level was significantly smaller in PVA peri-injection heart section
than PBS- or PDGF-AB–injected sections. However, there is significant
difference between 4- and 24-mo-old rats with PVA treatment. (B) Graph
shows average myocardial infarction size (percentage of left ventricular
area).  *, P    0.05. 4-mo-old PVA versus 4-mo-old PBS, 4-mo-old
PDGF-AB, and 24-mo-old PVA. **, P   0.05. 24-mo-old PVA versus
24-mo-old PBS and 24-mo-old PDGF-AB.Senescent Impairment in Synergistic Rapid Cardioprotective Pathways 802
cent cardiac allograft model support the well-documented
role of these cytokines in the promotion of cardiac vascu-
larization (24, 25). However, the immediate antiapoptotic
actions of the growth factor combination demonstrate that
the PDGF-AB–mediated protection from myocardial in-
jury may be based primarily on the suppression of acute cell
death of cardiac endothelial cells and myocytes. This anti-
apoptotic effect, in concert with the potential recruitment
of cardiovascular progenitor/stem cells and the growth of
new vascular supplies, acts to minimize the extent of myo-
cardial infarction.
Previous works have demonstrated that vascular cyto-
kines can have profound actions on apoptotic pathways.
Indeed, although VEGF and Angs are potent angiogenic
tyrosine kinase receptor growth factors (12, 26, 27), they
have also both been shown to be strong protectors of endo-
thelial cells from apoptosis (28, 29). Moreover, the wide-
spread suppression in myocardial cell death suggests that
PVA protection extends beyond the endothelial cells,
which express receptors for these growth factors. The ac-
tions of PVA may be mediated though direct cell–cell
communications in vascular cells (30, 31). The protection
of local cardiac myocytes may involve the induction of
other growth factors or paracrine pathways. To this end,
PDGF and VEGF can induce the antiapoptotic factor sur-
vivin (32, 33), suggesting another potential mechanism by
which the PVA treatment may promote autocrine and
paracrine antiapoptotic pathways to protect the myocar-
dium after coronary occlusion.
The paracrine actions of the triple growth factor combi-
nation may be mediated through subpopulations of resident
endothelial cells as well as endothelial progenitor cells re-
cruited into the cardiac microvasculature. Although cyto-
kines have been well documented to mobilize populations
of endothelial precursor cells from the bone marrow (34–
36), the observation that PDGF-AB treatment markedly
increases the number of PDGFR-  positive cardiac mi-
crovascular cells represents a novel finding. The mecha-
nisms underlying this induction are as yet unclear, though
they may involve the recruitment of PDGFR-  positive
endothelial progenitor cells to the cardiac microvasculature.
Previously, we demonstrated that endothelial progenitor
cells expressing PDGF-B are recruited to foci of angiogen-
esis in the cardiac microvasculature (6), and the actions of
PDGF-AB are mediated, in turn, by a subpopulation of
PDGFR-   cardiac endothelial cells (8). These findings, in
conjunction with the present observations, suggest that
PDGF may regulate positive feedback loops to maintain
subpopulations of endothelial progenitor cells that govern
its cardioprotective actions in the cardiac microvasculature.
Indeed, impairment in this loop, with dysregulation of
PDGF-B expression in the aging heart, correlates with the
significantly diminished density of PDGFR-  in the senes-
cent cardiac microvasculature. Reconstitution of this path-
way through intratmyocardial injection of PDGF-AB re-
sults in increased PDGFR-  cell levels in the aging heart to
those observed in the young cardiac tissue.
The role of vascular cytokines in the recruitment of spe-
cific subpopulations of endothelial progenitor cells may ex-
tend to the growth factors downstream from PDGF-AB in
the heart. The increase in both VEGF and Ang-2 correlate
with an augmentation in their respective receptors in the
microvasculature of the young hearts after injection of
PDGF-AB. The senescent impairment in VEGF and Ang-2
induction is associated with a lack of increase in Flk-1 and
Tie-2 cells. However, treatment of the older hearts with the
PVA combination provides significant cardioprotection,
suggesting that the reconstitution of the downstream cyto-
kines mediates the induction of their receptors in the cardiac
microvascular, likely through the induction of endothelial
progenitor cells. The diminished benefit of PVA in the
older hearts may reflect the lower baseline in receptor pop-
ulations in the hearts before treatment and acute coronary
occlusion, suggesting that a more sustained approach to pro-
moting PVA pathways may result in improved cardiopro-
tection for the aging heart. Indeed, elucidation of the pre-
cise mechanisms governing the increase in these receptor
subpopulations may provide approaches to further promote
cardioprotective pathways in all age groups.
In addition to promoting vascular protection, PDGF-AB
pathways could enhance the regeneration of cardiac myo-
cytes after myocardial injury. The coincident recruitment
of progenitors of cardiac endothelial cells and cardiac myo-
cytes by systemic mobilization (37) suggests that PVA-stim-
ulated pathways may also promote the cardiac homing
and/or differentiation of cardiac myocyte progenitor and/
or stem cells. Indeed, PDGF-AB–endothelial progenitor
cell communication pathways may provide a foundation
for the regeneration of cardiac myocytes in the injured
heart. Previous studies have demonstrated the transdifferen-
tiation capacity of endothelial cells (38). Moreover, recent
papers have revealed that endothelial–cardiac myocyte in-
teractions can promote the generation of additional cardiac
myocytes from cultures of embryonic endothelial cells (39)
and endothelial progenitor cells (40). These analyses suggest
that signals such as PDGF-B, which is induced in the co-
culture of endothelial progenitor cells and cardiac myocytes
(6), may mediate the induction of cardiac myocytes from
cells recruited to the treated hearts. Indeed, PDGF isoforms
have been demonstrated to promote the growth of embry-
onic cardiac myocytes, (41, 42) suggesting that PVA acting
with or through cardiovascular stem and/or progenitor
cells that are recruited to or reside within the heart (43)
may promote the regeneration of cardiac tissue to reduce
the extent of myocardial injury after coronary occlusion in
both younger and older hearts.
The age-associated decrease in PVA-mediated cardio-
protection may be due in part to senescent changes in the
cardiac vasculature. In addition to alterations in angiogenic
cytokine pathways that are critical in restoring vascular sup-
ply to compromised myocardial tissue, age-associated shifts
in vascular function can enhance apoptotic signaling further
and increase cardiac pathology in experimental models (20,
44). Furthermore, the senescent changes in VEGF andXaymardan et al. 803
Ang-2 expression patterns, with higher levels of expression
at baseline that are not increased by PDGF-AB, may be in-
fluenced by other age-dependent effects on gene regula-
tion. Indeed, direct effects of aging on endothelial cells, as
well as the alterations in the cardiac environment, includ-
ing increased reactive oxygen species (45, 46) and shifts in
hemostatic pathways (47, 48), may lead to a significant im-
pairment in endothelial function in the old heart. The
composite effect of these and potentially other age-associ-
ated physiologic actions may contribute to the decrease in
cardioprotective cytokine pathways observed in vivo.
Overall, our findings provide a unique insight to the
synergism of PDGF-AB pathways in the protection of the
rodent heart from myocardial infarction. Future studies di-
rected at identifying the set of antiapoptotic and proangio-
genic elements, as well as other potential cardioprotective
actions, including the recruitment of endothelial progenitor
cells, may facilitate the development of novel clinical ap-
proaches to limit the extent of myocardial injury in both
younger as well as older hearts.
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